| Literature DB >> 32195065 |
Faryal Tahir1, Jawad Ahmed1, Farheen Malik2.
Abstract
The spleen is an intraperitoneal organ that performs vital hematological and immunological functions. It maintains both innate and adaptive immunity and protects the body from microbial infections. The removal of the spleen as a treatment method was initiated from the early 1500s for traumatic injuries, even before the physiology of spleen was properly understood. Splenectomy has therapeutic effects in many conditions such as sickle cell anemia, thalassemia, idiopathic thrombocytopenic purpura (ITP), Hodgkin's disease, and lymphoma. However, it increases the risk of infections and, in some cases, can lead to a case of severe sepsis known as overwhelming post-splenectomy infection (OPSI), which has a very high mortality rate. Encapsulated bacteria form a major proportion of the invading organisms, of which the most common is Streptococcus pneumoniae. OPSI is a medical emergency that requires prompt diagnosis (with blood cultures and sensitivity, blood glucose levels, renal function tests, and electrolyte levels) and management with fluid resuscitation along with immediate administration of empirical antimicrobials. OPSI can be prevented by educating patients, vaccination, and antibiotic prophylaxis. This article summarizes the anatomy and physiology of the spleen and highlights its important functions. It primarily focuses on the pathophysiology of OPSI, its current management, and prevention strategies.Entities:
Keywords: asplenia; infection; opsi; overwhelming post-splenectomy infection; sepsis; spleen; splenectomy; vaccination
Year: 2020 PMID: 32195065 PMCID: PMC7059871 DOI: 10.7759/cureus.6898
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Schematic diagram of microstructure of the spleen
Neurovascular supply and lymphatic drainage of the spleen
| Characteristics | Structures involved |
| Arterial supply | Splenic artery, which further divides into five branches that do not anastomose, giving rise to vascular segmentation of the spleen |
| Venous drainage | Splenic vein, which later joins superior mesenteric vein to give rise to the portal vein |
| Innervation | Celiac plexus (sympathetic and parasympathetic) |
| Lymphatic drainage | Celiac lymph node (receives lymph from pancreaticosplenic lymph nodes) |
Functions of the spleen
IgM: immunoglobulin M
| Immunological functions | Hematological functions |
| Red pulp macrophages decontaminate the blood from pathogens | Removal of unwanted intra-erythrocytic inclusions, i.e., Howell–Jolly bodies and erythrocyte pits |
| Marginal zone macrophages get rid of the circulating microorganisms and cellular debris | Pooling of platelets along with sequestration of erythrocytes, granulocytes, plasmablasts, and plasma cells |
| Tingible body macrophages discard B-cell debris in the germinal center of the follicle | Phagocytosis of defective or old erythrocytes in the blood circulation |
| Dendritic cells, natural killer cells, and monocytes induce T lymphocyte formation | Hematopoiesis during fetal life |
| Splenic B cells produce antigen-specific antibodies and augment cytotoxic T cell response | Extramedullary hematopoiesis (if required) |
| IgM memory B cells produce IgM to promote the clearance of polysaccharide-encapsulated bacteria | Storage of iron |
| Production of immune mediators such as complement, opsonins, properdin, and tufts, which instigate phagocytosis |
Indications and contraindications for splenectomy
HS: hereditary spherocytosis; TB: tuberculosis; ITP: idiopathic thrombocytopenic purpura
| Absolute indications for splenectomy | Relative indications for splenectomy | Absolute contraindications for splenectomy | Relative contraindications for splenectomy (laparoscopic approach) |
| Splenic trauma, i.e., splenic rupture either spontaneous (tropical splenomegaly) or delayed (subcapsular hematoma) | Congenital or acquired hemolytic anemia | Uncorrectable coagulopathy | Active hemorrhage with hemodynamic instability |
| HS | Thalassemia | Severe cardiovascular disease making the patient unfit for general anesthesia | Non-platelet coagulopathy |
| Splenic abscess (TB infection) | Acute, chronic myeloid or chronic lymphatic leukemia | Cirrhosis with portal hypertension | Contraindications to pneumoperitoneum |
| Splenic cyst | Lymphoma (Hodgkin’s) | Splenomegaly | |
| As part of radical surgical removal of locally advanced gastric carcinoma, pancreatic carcinoma | Polycythaemia vera and myelofibrosis | Pregnancy | |
| Angioma | Acute or chronic ITP | Extensive previous upper abdominal surgery | |
| Primary splenic malignancy (rare) | Parasitic infestation, malaria, and Felty’s syndrome | ||
| Aneurysm of splenic artery | Angioma, cysts, and metastases | ||
| Bleeding esophageal varices secondary to splenic vein thrombosis | Tropical or non-tropical splenomegaly | ||
| Intrahepatic or extrahepatic portal hypertension | |||
| Amyloidosis and Gaucher’s disease |
Information and directions for splenectomized patients
OPSI: overwhelming post-splenectomy infection
| Summary of patient education details |
| Splenectomy carries a lifelong increased risk of infections |
| Initial symptoms of OPSI include high-grade fever (>38 °C), chills, myalgia, headache, vomiting, and abdominal pain |
| Please notify your healthcare workers about your asplenic status |
| Seek immediate medical attention on events like animal bites and scratches |
| Consider seeking medical advice prior to traveling, especially before visiting a malaria-endemic area |
| Always carry antibiotic supplies with you (may find helpful in case of sudden illness) |
| Never forget to carry a medical alert |
| If available, must consider registering in a “spleen registry system” |
CDC-recommended adult immunization schedule after splenectomy
CDC: Centers for Disease Control and Prevention; IM: intramuscular
| Recommended vaccine | Dose of the vaccine | Route of administration | Time of administration |
| In-hospital protocol | |||
| Pneumococcal 13-valent conjugate (PCV13: Prevnar 13) | 0.5 mL | IM | On the day of discharge or day 14, whichever comes first |
| Haemophilus influenza type b vaccine (Hib: ActHIB) | 0.5 mL | IM | On the day of discharge or day 14, whichever comes first |
| Meningococcal vaccine (Menactra) | 0.5 mL | IM | On the day of discharge or day 14, whichever comes first |
| Meningococcal serogroup B (Bexsero) | 0.5 mL | IM | On the day of discharge or day 14, whichever comes first |
| Short-term follow-up | |||
| Pneumococcal polysaccharide (PPSV23: Pneumovax 23) | 0.5 mL | IM | Two months after the initial vaccination |
| Meningococcal vaccine | 0.5 mL | IM | Two months after the initial vaccination |
| Meningococcal serogroup B | 0.5 mL | IM | Two months after the initial vaccination |
| Long-term follow-up | |||
| Pneumococcal polysaccharide | 0.5 mL | IM | 5 years after the first dose |
| Meningococcal vaccine | 0.5 mL | IM | Every 5 years |
| Seasonal influenza vaccine | - | - | Annually |
High-risk population who should be administered lifelong antibiotic prophylaxis after splenectomy
PPV: pneumococcal polysaccharide vaccine
| High-risk population |
| Children younger than 16 years of age |
| Adults older than 50 years of age |
| Individuals with a past history of invasive pneumococcal infection |
| Individuals splenectomized for hematologic malignant diseases, malignant neoplasms, and thalassemia |
| Individuals in the first year post-splenectomy, irrespective of the cause |
| Patients with sickle cell anemia |
| Individuals with a poor response to PPV-23 |